WithdrawnPHASE1, PHASE2NCT01733095

Ambrisentan for Treatment of Portopulmonary Hypertension

Studying Pulmonary arterial hypertension associated with portal hypertension

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Medical University of Graz
Principal Investigator: Rudolf E. Stauber, MD
Gastroenterology & Hepatology
Intervention: ambrisentan(drug)
Eligibility: 18 years · All sexes
Timeline: 2012 – 2016

Study locations (1)

Medical University of Graz, Graz, Austria

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01733095 on ClinicalTrials.gov

← Back to all trials